Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
- 1 January 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 2 (1), 80-90
- https://doi.org/10.1158/2326-6066.cir-13-0067
Abstract
Immunotherapy with intratumoral injection of adenoviral vectors expressing CD40L has yielded positive results in experimental and clinical bladder cancer. We therefore hypothesized that anti-CD40 antibody would be effective in this setting. Agonistic CD40 antibodies were developed as vaccine adjuvants but have later been used as treatment of advanced solid tumors and hematologic cancers. Systemic anti-CD40 therapy has been associated with immune-related adverse events, such as cytokine release syndrome and liver toxicity, and local delivery is an attractive approach that could reduce toxicity. Herein, we compared local and systemic anti-CD40 antibody delivery to evaluate efficacy, toxicity, and biodistribution in the experimental MB49 bladder cancer model. Antitumor effects were confirmed in the B16 model. In terms of antitumor efficacy, local anti-CD40 antibody stimulation was superior to systemic therapy at an equivalent dose and CD8 T cells were crucial for tumor growth inhibition. Both administration routes were dependent on host CD40 expression for therapeutic efficacy. In vivo biodistribution studies revealed CD40-specific antibody accumulation in the tumor-draining lymph nodes and the spleen, most likely reflecting organs with frequent target antigen-expressing immune cells. Systemic administration led to higher antibody concentrations in the liver and blood compared with local delivery, and was associated with elevated levels of serum haptoglobin. Despite the lack of a slow-release system, local anti-CD40 therapy was dependent on tumor antigen at the injection site for clearance of distant tumors. To summarize, local low-dose administration of anti-CD40 antibody mediates antitumor effects in murine models with reduced toxicity and may represent an attractive treatment alternative in the clinic. (C) 2013 AACR.Other Versions
This publication has 45 references indexed in Scilit:
- Intratumoral Delivery of Low Doses of Anti-CD40 mAb Combined With Monophosphoryl Lipid A Induces Local and Systemic Antitumor Effects in Immunocompetent and T Cell-Deficient MiceJournal of Immunotherapy, 2013
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumorsCancer Biology & Therapy, 2010
- Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?Clinical and Developmental Immunology, 2010
- Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG TherapyJournal of Immunotherapy, 2010
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myelomaHaematologica, 2010
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40British Journal of Cancer, 2008
- Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant MelanomaJournal of Immunotherapy, 2008
- Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primatesBritish Journal of Pharmacology, 2006
- Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005